Bahamasair and Emirates Partnership Activated, Offering Direct Connections to Nassau and Freeport GlobeNewswire December 05, 2025 Nassau, The Bahamas, Dec. 05, 2025 (GLOBE NEWSWIRE) — Bahamasair and Emirates have now moved their interline agreement from planning to operation, enabling travellers from Emirates' global network to connect through Florida to the islands of The Bahamas. Passengers […]

Olympus Corporation today announced a voluntary medical device corrective action for its Single-Use Ligating Device (“PolyLoop”) following identification of a potential safety issue. https://mma.prnewswire.com/media/1774929/Olympus_Logo.jpg The PolyLoop device is designed for use with Olympus endoscopes to deliver a nylon loop snare intended to prevent or control bleeding following polypectomy of pedunculated polyps. Olympus took this action

Vancouver, British Columbia–(Newsfile Corp. – December 5, 2025) – C21 Investments Inc. (CSE: CXXI) (OTCQX: CXXIF) (“C21” or the “Company“), a vertically integrated cannabis company, is pleased to announce that it intends to commence a renewed normal course issuer bid (the “NCIB“), under which it may purchase up to 5,898,596 common shares of the Company

(NasdaqGM:AVDL),(NASDAQ:ALKS), NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH

(NYSE:PSN), CHANTILLY, Va., Dec. 05, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced the company has secured a position on Sound Transit's 2025 $1 billion ceiling Multiple Award Task Order Contract (MATOC) for design services. This five-year contract, with two potential one-year extensions, will support Sound Transit's $60 billion capital program–one of the largest

(NasdaqGM:NTLA), CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2025, it awarded inducement grants to three new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grants

(NasdaqGM:HIFS), HINGHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — HINGHAM INSTITUTION FOR SAVINGS (NASDAQ:HIFS) (“the Bank”), Hingham, Massachusetts, announced that its Board of Directors has authorized a share repurchase program (“the Program”) pursuant to which the Bank may repurchase up to $20 million of its outstanding common stock, having received all regulatory approvals as may

(NasdaqGM:NAMS),(NasdaqGM:NAMSW), NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or

(NasdaqGM:KYMR), Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase

Announcement relating to despatch of Rule 15 proposal GlobeNewswire December 05, 2025 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF